Recent Updates — ALVOW
The U.S. Food and Drug Administration approved a supplement to the Biologics License Application for AVT02 (SIMLANDI), enabling drug substance production in a second suite, DSM2, at Alvotech's Reykjavik facility. This approval doubles the manufacturing capacity available to support U.S. commercial supply of the biosimilar to Humira and confirms the resolution of prior inspection-related matters at the site. The company expects this regulatory milestone to facilitate action on other pending applications for its pipeline candidates. Alvotech is a biotechnology company focused on the development and manufacture of biosimilar medicines.
Alvotech announced a strategic licensing and commercialization agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab (AVT34) and emicizumab (AVT87). The deal grants Alvotech semi-exclusive rights in the U.S., where it retains development responsibility and serves as exclusive supplier, while Lotus commercializes via subsidiary Alvogen. Lotus holds exclusive rights in eight Asian markets including South Korea and Taiwan. The agreement has a potential value of up to $150 million in upfront and milestone payments plus ongoing supply revenues. Alvotech is a biotechnology company specializing in the development and manufacture of biosimilar medicines.
Alvotech reported a net loss of $65.8 million for the six months ended June 30, 2026, compared to a net profit of $141.7 million in the prior-year period. Product revenue declined 48% to $105.9 million due to manufacturing disruptions following an FDA inspection, while license and milestone revenue rose 4.4% to $105.7 million. The company completed an equity financing in June 2026 generating gross proceeds of $164.6 million and secured a $75.0 million financing facility. General and administrative expenses increased to $69.2 million, largely driven by a $20.2 million provision for commercial matters. Alvotech operates as a biopharmaceutical company specializing in the development and manufacturing of biosimilar medicines.
Alvotech announced that the U.S. Food and Drug Administration closed its May 2026 inspection of the Reykjavik manufacturing facility with a Voluntary Action Indicated (VAI) classification. CEO Lisa Graver stated this milestone reflects strengthened quality systems and addresses prior observations, supporting ongoing regulatory efforts for Biologics Licence Applications. The company also highlighted recent pipeline updates, including BLA resubmissions for biosimilars AVT05 (golimumab) and AVT06 (aflibercept), and FDA acceptance of a BLA for AVT16 (vedolizumab). Alvotech is a biotechnology company specializing in the development and manufacture of biosimilar medicines.